These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9851962

  • 1. Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis.
    Riesbeck K, Chen D, Kemball-Cook G, McVey JH, George AJ, Tuddenham EG, Dorling A, Lechler RI.
    Circulation; 1998 Dec 15; 98(24):2744-52. PubMed ID: 9851962
    [Abstract] [Full Text] [Related]

  • 2. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins.
    Chen D, Riesbeck K, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A.
    Xenotransplantation; 2001 Nov 15; 8(4):258-65. PubMed ID: 11737851
    [Abstract] [Full Text] [Related]

  • 3. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins.
    Chen D, Riesbeck K, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A.
    Transplantation; 1999 Sep 27; 68(6):832-9. PubMed ID: 10515384
    [Abstract] [Full Text] [Related]

  • 4. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
    Peter K, Gupta A, Nordt T, Bauer S, Runge MS, Bode C.
    J Cardiovasc Pharmacol; 2003 Aug 27; 42(2):237-44. PubMed ID: 12883328
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins.
    Chen D, Riesbeck K, Kemball-Cook G, McVey JH, Tuddenham EG, Lechler RI, Dorling A.
    Transplantation; 1999 Feb 15; 67(3):467-74. PubMed ID: 10030296
    [Abstract] [Full Text] [Related]

  • 6. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.
    Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kübler W, Little M, Bode C.
    Circulation; 2000 Mar 14; 101(10):1158-64. PubMed ID: 10715263
    [Abstract] [Full Text] [Related]

  • 7. Electrostatic steering and ionic tethering in the formation of thrombin-hirudin complexes: the role of the thrombin anion-binding exosite-I.
    Myles T, Le Bonniec BF, Betz A, Stone SR.
    Biochemistry; 2001 Apr 24; 40(16):4972-9. PubMed ID: 11305913
    [Abstract] [Full Text] [Related]

  • 8. Antithrombin effects of native and recombinant hirudins.
    Markwardt F, Stürzebecher J, Glusa E.
    Biomed Biochim Acta; 1990 Apr 24; 49(5):399-404. PubMed ID: 2271010
    [Abstract] [Full Text] [Related]

  • 9. Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.
    Chen D, McVey JH, Dorling A.
    Thromb Res; 2013 Apr 24; 132(6):750-6. PubMed ID: 24161661
    [Abstract] [Full Text] [Related]

  • 10. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin.
    Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E, Newell JB, Kübler W, Haber E, Runge MS.
    Circulation; 1994 Oct 24; 90(4):1956-63. PubMed ID: 7923685
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and secretion of hirudin by Streptomyces lividans.
    Bender E, Vogel R, Koller KP, Engels J.
    Appl Microbiol Biotechnol; 1990 Nov 24; 34(2):203-7. PubMed ID: 1367034
    [Abstract] [Full Text] [Related]

  • 13. Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins.
    Rade JJ, Cheung M, Miyamoto S, Dichek DA.
    Gene Ther; 1999 Mar 24; 6(3):385-92. PubMed ID: 10435088
    [Abstract] [Full Text] [Related]

  • 14. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity.
    Kaminski M, Siebenlist KR, Mosesson MW.
    J Lab Clin Med; 1991 Mar 24; 117(3):218-25. PubMed ID: 2002278
    [Abstract] [Full Text] [Related]

  • 15. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
    Lu WF, Mo W, Liu Z, Fu WG, Guo DQ, Wang YQ, Song HY.
    Thromb Res; 2010 Oct 24; 126(4):e339-43. PubMed ID: 20483158
    [Abstract] [Full Text] [Related]

  • 16. Factor X fusion proteins: improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein.
    Guarna MM, Côté HC, Kwan EM, Rintoul GL, Meyhack B, Heim J, MacGillivray RT, Warren RA, Kilburn DG.
    Protein Expr Purif; 2000 Nov 24; 20(2):133-41. PubMed ID: 11049737
    [Abstract] [Full Text] [Related]

  • 17. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
    Roddick LA, Bhakta V, Sheffield WP.
    BMC Biochem; 2013 Nov 11; 14():31. PubMed ID: 24215622
    [Abstract] [Full Text] [Related]

  • 18. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.
    Prasa D, Svendsen L, Stürzebecher J.
    Thromb Haemost; 1997 Mar 11; 77(3):498-503. PubMed ID: 9066001
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.